DMAAU

FINANCIAL SERVICES

Drugs Made In America Acquisition Corp. Units

$10.58+0.00 (+0.00%)LIVE

Live · NASDAQ · May 13, Close

AI Insight

What's Moving DMAAU Today?

No stock-specific AI insight has been generated for DMAAU yet. Check back soon — insights are generated from recent news analysis.

52-Week Range

$10.25$10.60

$10.58

Fundamentals

Market Cap$309M

P/E Ratio—

EPS—

Dividend Yield—

Dividend / Share—

ROE—

Profit Margin—

Debt / Equity—

Trading

Volume—

Avg Volume (10D)—

Shares Outstanding29.2M

DMAAU News

1 article

Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) is definitely on the radar of institutional investors who own 38% of the companyYahoo Finance·Aug 16, 2025

All 1 articles loaded

Price Data

Open—

Previous Close—

Day High—

Day Low—

52 Week High$10.60

52 Week Low$10.25

52-Week Range

$10.25$10.60

$10.58

Fundamentals

Market Cap$309M

P/E Ratio—

EPS—

Dividend Yield—

Dividend / Share—

ROE—

Profit Margin—

Debt / Equity—

Trading

Volume—

Avg Volume (10D)—

Shares Outstanding29.2M

About Drugs Made In America Acquisition Corp. Units

Drugs Made In America Acquisition Corp. Units (DMAAU) is a special purpose acquisition company (SPAC) dedicated to merging with pioneering companies in the pharmaceutical and healthcare industries. Backed by a seasoned management team with deep sector expertise, DMAAU aims to drive transformative growth and enhance the accessibility of medicines in the U.S. As the focus on domestic drug manufacturing intensifies, DMAAU presents a strategic opportunity for institutional investors looking to participate in the evolving landscape of health technology and the pharmaceutical sector's shift toward innovation and affordability.

dmaacorp.com

Listed January 28, 2025

FINANCIAL SERVICESSHELL COMPANIES

Company Details

Security TypeCommon Stock

ExchangeNASDAQ

CurrencyUSD

Round Lot—

SICSHELL COMPANIES

CIK—

Composite FIGI—

Share Class FIGI—